Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growthfactor expression in non-small cell lung cancer;Küçük hücreli dışı akciǧer kanserli hastalarda matriks metalloproteinaz (MMP-9 ve MMP-2) ve vasküler epitelyal büyüme faktörü ekspresyonunun prognoz üzerine olan etkisi

Turkish Journal of Medical Sciences

Volumn 42, Issue 2, 2012, Pages 281-288

  Yurdakul, Ahmet ^a   Akyürek, Nalan ^a   Yilmaz, Şenay ^a   Karakaya, Jale ^b   Memiş, Leyla ^a   Öztürk, Can ^a  

^a GAZI UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Lung cancer; Matrix metalloproteinases; Metastasis; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; VASCULOTROPIN;

ADULT; ARTICLE; BASEMENT MEMBRANE; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEMBRANE DAMAGE; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR VASCULARIZATION;

EID: 84857480330     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1012-1361     Document Type: Article

References (40)

1. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon, France: IARC Press; 2004.
2. Tuncer M, Ozgul M, Olcayto EO, Gultekin M, Erdin B. Republic of Turkey Ministry of Health, Department of Cancer Control, National Cancer Program, 2009-2015. Ministry Publication No: 760. Ankara: Ministry of Health; 2009 [in Turkish].
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
4. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-94.
5. Matsui K, Kitagawa M, Sugiyama S, Yamamoto K. Distribution pattern of the basement membrane components is one of the significant prognostic correlates in peripheral lung adenocarcinomas. Hum Pathol 1995; 26: 186-94.
6. Hrabec E, Strek M, Nowak D, Greger J, Suwalski M, Hrabec Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol 2002; 128: 197-204.
7. Culhaci N, Metin K, Copcu E, Dikicioglu E. Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer 2004; 4: 42-51.
8. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF et al. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 1994; 145: 1285-90.
9. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE. Expression of metalloproteinase and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992; 66: 1188-94.
10. Sawicki G, Matsuzaki A, Jankowska-Wieczorek A. Expression of the active form of MMP-2 on the surface of leukemic cells accounts for their in vitro invasion. J Cancer Res Clin Oncol 1998; 124: 245-52.
11. Ohta Y, Watanabe Y. Current concepts of angiogenesis related to primary lung cancer. In: Lung cancer. Pass IH, editor. 2nd ed. Philadelphia (PA): Lippincott Williams-Wilkins; 2000. p.199-210.
12. Robbins SL, Kumar V. Neoplasia. In: Cotran RS, Vinay K, Collins T, Robbins SL, editors. Robbins & Cotran Pathologic basis of disease. 6th ed. Philadelphia (PA): W.B. Saunders Company; 1999. p.301-2.
13. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small cell lung cancer. Br J Cancer 2001; 85: 1706-12.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
15. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 2001; 33: 17-24.
16. Poon RTP, Fan TS, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-25.
17. Aikawa H, Takahashi H, Fujimura S, Sato M, Endo C, Sakurada A et al. Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer. Anticancer Res 1999; 19: 4305-10.
18. Ohta Y, Tomita Y, Oda M, Watanabe S, Murakami S, Watanabe Y et al. Tumor angiogenesis and recurrence in stage I nonsmall cell lung cancer. Ann Thorac Surg 1999; 68: 1034-8.
19. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 2001; 33: 125-32.
20. Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78: 765-70.
21. Volm M, Koomagi R, Mattern J. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association wiThlymph node metastasis. Anticancer Res 1999; 19: 651-6.
22. Volm M, Mattern J, Koomagi R. Angiostatin expression in non-small cell lung cancer. Clin Cancer Res 2000; 6: 3236-40.
23. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42.
24. Cox G, Jones JL, Walker RA, Steward WP, O'Byrne KJ. Angiogenesis and non-small cell lung cancer. Lung Cancer 2000; 27: 81-100.
25. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 1997; 72: 556-64.
26. Werner JA, Rathcke IO, Mandic R. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastas 2002; 19: 275-82.
27. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho- Kere U, Kahari VM et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151: 499-508.
28. Yoskizaki T, Maruyama Y, Sato H, Furukawa M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 2001; 95: 44-50.
29. Bredin CG, Liu Z, Klominek J. Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines. Anticancer Res 2003; 23: 5372.
30. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 2000; 190: 150-6.
31. Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y et al. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004; 10: 6579-85.
32. Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2- complex or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 2006; 236: 125-32.
33. Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in nonsmall cell lung cancer. Histol Histopathol 2008; 23: 693-700.
34. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sata H, Aida S et al. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non-small cell lung carcinomas. Lung Cancer 2002; 35: 249-55.
35. Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH et al. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Japan J Clin Oncol 2006; 36: 263-8.
36. Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y et al. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review wiThmetaanalysis. Cancer Invest 2010; 28: 661-9.
37. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, β-catenin and prognosis. Lung Cancer 2006; 51: 313-21.
38. Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003; 103: 647-51.
39. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growThfactor signal pathway in operable nonsmall cell lung cancer. Clin Cancer Res 2000; 6: 2349-55.
40. Schutz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, Wittekind C. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol 2002; 23: 179-84.